Tirzepatide showed greater improvement in general health quality of life scores compared to semaglutide in adults with obesity, especially in those with limited baseline physical function.
General Health: 5.45 vs 4.20 (p=0.003)Tirzepatide produced significantly greater improvement in self-reported general health compared to semaglutide at 72 weeks in adults with obesity.
What the researchers found
At Week 72, both tirzepatide and semaglutide improved Physical Component Summary scores from baseline. Tirzepatide showed significantly greater improvement in General Health domain scores compared to semaglutide (5.45 vs. 4.20; p = 0.003). All SF-36v2 domain scores improved with both treatments (p ≤ 0.008).
In the subgroup with limited baseline physical function, tirzepatide outperformed semaglutide in Physical Component Summary, Physical Functioning, and General Health scores (p ≤ 0.025). Greater body weight reductions were associated with more improvement in Physical Functioning, Role-Physical, Bodily Pain, General Health, and Vitality scores across both treatments when pooled. Mental Component Summary scores did not differ significantly between treatments.
Why it matters
This is the first head-to-head comparison of quality of life outcomes between tirzepatide and semaglutide — the two leading peptide-based obesity treatments. Beyond weight loss numbers, quality of life is what matters most to patients. Finding that tirzepatide provides an edge in general health perception, particularly for patients with physical limitations, helps clinicians and patients make more informed treatment decisions.
How the study worked
This is a prespecified analysis of health-related quality of life data from the SURMOUNT-5 randomized controlled trial. On-treatment data from participants receiving at least one dose of tirzepatide or semaglutide at maximum tolerated dose were analyzed at Week 72. Outcomes included SF-36v2 norm-based scores (Physical and Mental Component Summaries and individual domains), Patient Health Questionnaire-9, and Patient Global Impression of Status for Physical Activity. Post hoc analyses examined outcomes by baseline physical function and by body weight reduction thresholds.
What this study cannot tell us
The quality of life analysis uses on-treatment data, which may overestimate benefits by excluding participants who discontinued due to side effects. The general health domain difference, while statistically significant, is modest in absolute terms. Mental health scores did not differ between treatments, and some subgroup analyses were post hoc. The study enrolled adults without type 2 diabetes, so results may not generalize to the diabetic obesity population.
How to read the evidence
This is a prespecified analysis from a randomized controlled head-to-head trial (SURMOUNT-5), representing high-quality clinical evidence. However, it measures quality of life as a secondary outcome, and some subgroup analyses were post hoc.
When this study was published
Published in 2026, this is the most current evidence from the landmark SURMOUNT-5 head-to-head trial comparing the two dominant peptide-based obesity therapies.
The bigger picture
The competition between GLP-1 and dual GIP/GLP-1 peptide agonists is one of the most important developments in modern pharmacology. Tirzepatide (dual agonist) has already shown greater weight loss than semaglutide (GLP-1 only) in SURMOUNT-5. This quality-of-life analysis adds another dimension to the comparison, suggesting the additional GIP pathway activation may provide benefits beyond what the scale shows.
Questions still open
- Does the general health quality of life advantage of tirzepatide persist beyond 72 weeks?
- Would the differences be larger or smaller in patients with type 2 diabetes and obesity?
- Is the general health improvement driven primarily by greater weight loss with tirzepatide, or are there independent effects?
Common questions
What is the difference between tirzepatide and semaglutide?
Does 'better quality of life' mean tirzepatide is clearly the better drug?
Read the original research
Improved health-related quality of life with tirzepatide versus semaglutide in adults with obesity or overweight from the SURMOUNT-5 trial.
Diabetes, obesity & metabolism, 28(1), 452-462
Citation
Shukla, Alpana P; Dunn, Julia P; Gomez Valderas, Elisa; Fraseur Brumm, Julia; Karanikas, Chrisanthi A; Hunter Gibble, Theresa. (2026). Improved health-related quality of life with tirzepatide versus semaglutide in adults with obesity or overweight from the SURMOUNT-5 trial.. Diabetes, obesity & metabolism, 28(1), 452-462. https://doi.org/10.1111/dom.70215